Literature DB >> 24069506

Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.

Marc Y Fink1, Jerry E Chipuk.   

Abstract

HER2 is overexpressed in a subset of breast cancers and controls an oncogenic signaling network that inhibits tumor cell death through the specific biochemical regulation of apoptotic pathways. In particular, the mitochondrial pathway for apoptosis is important for death induced by inhibitors of HER2. This review focuses on the connections between this oncogenic signaling network and individual components of the mitochondrial pathway. A comprehensive view of this signaling network is crucial for developing novel drugs in this area and to gain an understanding of how these regulatory interactions are altered in drug-refractory cancers.

Entities:  

Keywords:  AKT; BAD; BCL-2; lapatinib; mTOR; trastuzumab

Year:  2013        PMID: 24069506      PMCID: PMC3782004          DOI: 10.1177/1947601913488598

Source DB:  PubMed          Journal:  Genes Cancer        ISSN: 1947-6019


  108 in total

1.  Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway.

Authors:  X Fang; S Yu; A Eder; M Mao; R C Bast; D Boyd; G B Mills
Journal:  Oncogene       Date:  1999-11-18       Impact factor: 9.867

Review 2.  The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions.

Authors:  Seunghee Yoon; Rony Seger
Journal:  Growth Factors       Date:  2006-03       Impact factor: 2.511

3.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.

Authors:  Rita Nahta; Linda X H Yuan; Bing Zhang; Ryuji Kobayashi; Francisco J Esteva
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

Review 4.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Authors:  Devika Gajria; Sarat Chandarlapaty
Journal:  Expert Rev Anticancer Ther       Date:  2011-02       Impact factor: 4.512

5.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

Authors:  Qing-Bai She; David B Solit; Qing Ye; Kathryn E O'Reilly; Jose Lobo; Neal Rosen
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

7.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

8.  Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.

Authors:  E Yang; J Zha; J Jockel; L H Boise; C B Thompson; S J Korsmeyer
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1.

Authors:  Mario Campone; Bélinda Noël; Cécile Couriaud; Morgan Grau; Yannis Guillemin; Fabien Gautier; Wilfried Gouraud; Catherine Charbonnel; Loïc Campion; Pascal Jézéquel; Frédérique Braun; Benjamin Barré; Olivier Coqueret; Sophie Barillé-Nion; Philippe Juin
Journal:  Mol Cancer       Date:  2011-09-07       Impact factor: 27.401

10.  Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses.

Authors:  Marc R Birtwistle; Mariko Hatakeyama; Noriko Yumoto; Babatunde A Ogunnaike; Jan B Hoek; Boris N Kholodenko
Journal:  Mol Syst Biol       Date:  2007-11-13       Impact factor: 11.429

View more
  14 in total

Review 1.  Single compartment drug delivery.

Authors:  Michael J Cima; Heejin Lee; Karen Daniel; Laura M Tanenbaum; Aikaterini Mantzavinou; Kevin C Spencer; Qunya Ong; Jay C Sy; John Santini; Carl M Schoellhammer; Daniel Blankschtein; Robert S Langer
Journal:  J Control Release       Date:  2014-05-04       Impact factor: 9.776

Review 2.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

Review 3.  Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Authors:  Haroon A Hussain; Amanda J Harvey
Journal:  World J Clin Oncol       Date:  2014-08-10

4.  Loss of H3K27 Trimethylation Promotes Radiotherapy Resistance in Medulloblastoma and Induces an Actionable Vulnerability to BET Inhibition.

Authors:  Nishanth Gabriel; Kumaresh Balaji; Kay Jayachandran; Matthew Inkman; Jin Zhang; Sonika Dahiya; Michael Goldstein
Journal:  Cancer Res       Date:  2022-05-16       Impact factor: 13.312

Review 5.  Targeting apoptosis in cancer therapy.

Authors:  Benedito A Carneiro; Wafik S El-Deiry
Journal:  Nat Rev Clin Oncol       Date:  2020-03-23       Impact factor: 66.675

6.  PAQR3 expression is downregulated in human breast cancers and correlated with HER2 expression.

Authors:  Zhenghu Li; Zhi-Qiang Ling; Weiwei Guo; Xiao-Xiao Lu; Yi Pan; Zhenzhen Wang; Yan Chen
Journal:  Oncotarget       Date:  2015-05-20

7.  Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.

Authors:  Sergey V Karakashev; Mauricio J Reginato
Journal:  Oncotarget       Date:  2015-02-10

8.  Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2-Akt axis.

Authors:  B S Vinod; H H Nair; V Vijayakurup; A Shabna; S Shah; A Krishna; K S Pillai; S Thankachan; R J Anto
Journal:  Cell Death Discov       Date:  2015-12-07

9.  Experimental study of a novel tumstatin on C6 brain glioma in vitro.

Authors:  Pengguo Zhang; Qingwei Zhou; Lin Tian; Xiangyu Zhou; Yue Zhou; Jiajun Chen
Journal:  Oncol Lett       Date:  2017-06-30       Impact factor: 2.967

10.  Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.

Authors:  Marlies Gijs; Gregory Penner; Garth B Blackler; Nathalie R E N Impens; Sarah Baatout; André Luxen; An M Aerts
Journal:  Pharmaceuticals (Basel)       Date:  2016-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.